CompletedNot Applicable

Probiotic and Synbiotic Supplements in Hemodialysis Patients

Egypt60 participantsStarted 2025-03-01

Plain-language summary

This single-center randomized controlled trial evaluated the effects of natural probiotic and synbiotic supplementation on clinical and biochemical characteristics in adults with end-stage renal disease receiving maintenance hemodialysis at the Urology and Nephrology Center, Mansoura University, Egypt. Participants were randomized into three groups (control, probiotic, and synbiotic), with supplementation given for 6 months in the intervention groups. The study assessed changes in uremic toxins (including p-cresyl sulfate) as the primary outcome, and cardiovascular parameters, quality of life, and cognitive function as secondary outcomes. The trial aimed to determine whether modulation of gut microbiota with probiotics or synbiotics can improve outcomes in hemodialysis patients

Who can participate

Age range18 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 years or older. * End-stage renal disease patients on regular maintenance hemodialysis * Not under active preparation for kidney transplantation within the next year (i.e., not planned for transplantation for more than one year) Exclusion Criteria: * Age less than 18 years * Under active preparation for kidney transplantation * Pregnancy * Active malignancy * Known structural gastrointestinal tract disease

What they're measuring

Change in Serum p-Cresyl Sulfate (PCS)

Timeframe: Baseline and 6 months

Trial details

NCT IDNCT07531186

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-30

View on ClinicalTrials.gov More End Stage Renal Disease (ESRD) trials